

Mood

Phoenix Life

Product Description

Phoenix Mood is designed for managing anxiety and other mood disorders, reducing fear response and providing a level of disconnection with anxiety triggers. Further, with twice daily doses, Phoenix Mood has been designed as an everyday tool for managing mood issues while reducing the associated highs and lows.

Cannabinoid Extract Proprietor Compound

CANNABIDIOL (CBD), TETRAHYRDRACANNABINOL (THC),
AND OTHER TRACE CANNABINOIDS
A-HUMULENE , B-CARYOPHYLLENE , B-MYRCENE,
LINALOOL , P-CYMENE

Other Ingredients

Medium-chain triglycerides (MCT) derived from coconut, Water, Glycerin, Cannabis Extracts, Kolliphor HS-15, Peppermint Oil.

Global Distribution Strategy

Phoenix Mood is classified as a specific formulation and dosing product that may be exempted or scheduled under a specific country regulations governing pharmaceuticals and drug control. The product must be produced, distributed and sold through licensed medical cannabis facilities and pharmaceutical distribution licensed to handle tetrahydrocannabinol. Distribution will be from Vanuatu and state to state US manufacturing.

Online

This product is classified as containing high amounts of "THC from Cannabis" and therefore can only be sold through licensed agencies. Phoenix Mood Online ordering a provides for pick-up from a licensed distributor. Sold as Phoenix Mood(LE), without specific medical claims within the jurisdictions offered, unless otherwise approved.

Australia

Partner with local licensed producer for distribution under medical cannabis laws. Local clinical trials to be completed in 2026.

Europe

Partner with local licensed distributor under medical cannabis laws. Local clinical trials to be completed in 2026.

Global Distribution

Now that 47 countries have legalized medical cannabis, the inter-country trade is starting to expand. Phoenix Life is focused on import and export of its products from company owned and partnered production facilities. Phoenix Mood can only be sold through licensed agencies through local production and export to over 40 countries.

United States

State to state distribution under product licensing agreement with Equaliti. Clinical trials to be commenced late 2026.

Vanuatu

May be supplied under Dr Approval. Local Supply expected in 2022.

Medical History and Development Information

Initial Studies with a group of veterans showed reduction in symptoms and responses generally associated with post-traumatic-stress-disorder Dose models have been targeted to maximize symptomatic reduction and minimizing impairment. The product is designed to be sold in Soft Gel Capsules and Sub-lingual Sprays.

Clinical Stage

INITIAL CANDIDATE STRAIN / FORMULATION SELECTED
EFFICACY DATA COLLABORATED WITH RESEARCH TEAM
INITIAL PATIENT GROUP SUCCESS
LARGER PATIENT GROUP SUCCESS
FORMALIZED CLINICAL TRIALS
APPROVED FOR SALE IN LOCAL MARKET
EXEMPTION AVAILABLE FOR IMMEDIATE SALES

LEGEND ☐ Completed ☐ Next Step ☐ Not Completed

Medical Evidence, Citations and other References

US National Library of Medicine - a part of the National Institutes of Health details the following study and abstract More details are available at https://pubmed.ncbi.nlm.nih.gov/24923339/ 2014;13(6):953-60. DOI: 10.2174/1871527313666140612114838 PMID: 24923339

Antidepressant-like and anxiolytic-like effects of cannabidiol: a chemical compound of Cannabis sativa

Author(s): Alexandre R de Mello Schier, Natalia P de Oliveira Ribeiro, Danielle S Coutinho, Sergio Machado, Oscar Arias-CarriV≥n, Jose A Crippa, Antonio W Zuardi, Antonio E Nardi, Adriana C Silva

Abstract: Anxiety and depression are pathologies that affect human beings in many aspects of life, including social life, productivity and health. Cannabidiol (CBD) is a constituent non-psychotomimetic of Cannabis sativa with great psychiatric potential, including uses as an antidepressant-like and anxiolytic-like compound. The aim of this study is to review studies of animal models using CBD as an anxiolytic-like and antidepressant-like compound. Studies involving animal models, performing a variety of experiments on the above-mentioned disorders, such as the forced swimming test (FST), elevated plus maze (EPM) and Vogel conflict test (VCT), suggest that CBD exhibited an anti-anxiety and antidepressant effects in animal models discussed. Experiments with CBD demonstrated non-activation of neuroreceptors CB1 and CB2. Most of the studies demonstrated a good interaction between CBD and the 5-HT1A neuro-receptor.

Phoenix Life Sciences Pty Ltd
Level 16, No1 Martin Place Sydney Australia

www.phoenixlife.co